Prelude Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,204
| Closed | -$208K | – | 1285 |
|
|
2026
Q1 | $208K | Buy |
1,204
+45
| +4% | +$8.34K | 0.02% | 898 |
|
|
2025
Q4 | $231K | Buy |
+1,159
| New | +$210K | 0.02% | 961 |
|
|
2025
Q1 | – | Sell |
-1,360
| Closed | -$251K | – | 1248 |
|
|
2024
Q4 | $251K | Buy |
+1,360
| New | +$262K | 0.02% | 881 |
|
|
2024
Q3 | – | Sell |
-3,255
| Closed | -$672K | – | 1326 |
|
|
2024
Q2 | $672K | Sell |
3,255
-3,487
| -52% | -$790K | 0.05% | 419 |
|
|
2024
Q1 | $1.83M | Buy |
6,742
+1,464
| +28% | +$350K | 0.1% | 255 |
|
|
2023
Q4 | $1.25M | Buy |
+5,278
| New | +$1.04M | 0.08% | 252 |
|
|
2023
Q1 | – | Sell |
-3,235
| Closed | -$705K | – | 1231 |
|
|
2022
Q4 | $705K | Buy |
3,235
+2,197
| +212% | +$480K | 0.04% | 459 |
|
|
2022
Q3 | $204K | Sell |
1,038
-198
| -16% | -$42.7K | 0.01% | 1067 |
|
|
2022
Q2 | $264K | Sell |
1,236
-1,305
| -51% | -$319K | 0.01% | 1130 |
|
|
2022
Q1 | $722K | Buy |
+2,541
| New | +$784K | 0.02% | 709 |
|
|
2019
Q2 | – | Sell |
-56
| Closed | -$8K | – | 1746 |
|
|
2019
Q1 | $8K | Hold |
56
| – | – | ﹤0.01% | 1503 |
|
|
2018
Q4 | $6K | Buy |
+56
| New | +$7.01K | ﹤0.01% | 1519 |
|
|
2017
Q4 | – | Sell |
-3,039
| Closed | -$328K | – | 1411 |
|
|
2017
Q3 | $328K | Buy |
3,039
+477
| +19% | +$49K | 0.03% | 492 |
|
|
2017
Q2 | $259K | Sell |
2,562
-327
| -11% | -$30.1K | 0.02% | 499 |
|
|
2017
Q1 | $260K | Sell |
2,889
-139
| -5% | -$11.8K | 0.02% | 474 |
|
|
2016
Q4 | $231K | Buy |
3,028
+1,305
| +76% | +$99.1K | 0.03% | 528 |
|
|
2016
Q3 | $144K | Buy |
+1,723
| New | +$144K | 0.02% | 676 |
|
|
2016
Q1 | – | Sell |
-1,111
| Closed | -$89K | – | 1305 |
|
|
2015
Q4 | $89K | Buy |
1,111
+911
| +456% | +$65.7K | 0.01% | 854 |
|
|
2015
Q3 | $13K | Sell |
200
-5,689
| -97% | -$409K | ﹤0.01% | 1316 |
|
|
2015
Q2 | $414K | Hold |
5,889
| – | – | 0.06% | 354 |
|
|
2015
Q1 | $467K | Buy |
+5,889
| New | +$434K | 0.06% | 362 |
|
|
2014
Q1 | – | Sell |
-180
| Closed | -$10K | – | 1906 |
|
|
2013
Q4 | $10K | Buy |
180
+80
| +80% | +$4.02K | ﹤0.01% | 1503 |
|
|
2013
Q3 | $5K | Buy |
+100
| New | +$4.59K | ﹤0.01% | 1461 |
|
Other funds holding CRL
AI
Prelude Capital Management's CRL Position: Q2 2026 in Review
Prelude Capital Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 1,204 shares — an estimated $208K sold.
Prelude Capital Management first reported a position in CRL in Q3 2013 and held it in 23 quarters. The position peaked at $1.83M in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Prelude Capital Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- Prelude Capital Management sold 1,204 Charles River Laboratories shares in Q2 2026, an estimated $208K.
- Prelude Capital Management first reported a position in Charles River Laboratories in Q3 2013 and held it in 23 quarters.
- Prelude Capital Management's Charles River Laboratories position peaked at $1.83M in Q1 2024.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.